山河药辅(300452) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was CNY 121,190,834.76, up 14.27% year-on-year[8] - Net profit attributable to shareholders decreased by 13.46% to CNY 18,309,092.14 compared to the same period last year[8] - Basic earnings per share decreased by 12.93% to CNY 0.1024[8] - Diluted earnings per share also decreased by 12.93% to CNY 0.1024[8] - Weighted average return on equity was 3.48%, down 0.67% from the previous year[8] - The company reported a net cash decrease of RMB 39.39 million, a year-on-year decrease of 162.44%, primarily due to cash flow increases from operating and financing activities[23] - Net profit for the period was CNY 17,892,269.14, a decrease from CNY 23,313,825.96 in the same quarter last year, representing a decline of approximately 23.5%[43] - Earnings per share (EPS) for the quarter was CNY 0.1024, down from CNY 0.1176 in the previous year[44] - The company reported a profit before tax of CNY 79,379,465.26, an increase from CNY 76,223,323.06 in the previous year, showing a growth of 2.83%[51] - The total comprehensive income for the quarter was CNY 68,658,514.61, compared to CNY 66,556,862.15 in the same period last year, marking a 3.16% increase[53] Assets and Liabilities - Total assets increased by 2.87% to CNY 833,386,822.34 compared to the end of the previous year[8] - Total liabilities decreased to CNY 202,396,510.66 from CNY 213,592,625.98, a reduction of about 5.5%[35] - Current assets totaled CNY 412,344,918.38, up from CNY 380,901,424.79 at the end of 2019, reflecting a growth of approximately 8.5%[33] - Total limited shares at the end of the reporting period were 38,139,164 shares, with 8,801,345 shares released from restrictions during the period[17] - The total assets amounted to ¥810,166,507.12, with a slight increase from ¥810,124,444.25 in the previous year[70] - The total liabilities were ¥213,592,625.98, showing a minor increase from ¥213,550,563.11 in the previous year[70] - The total equity attributable to shareholders was ¥525,776,925.46, unchanged from the previous year[70] Cash Flow - Net cash flow from operating activities was negative at CNY -9,688,831.86, a decrease of 164.29%[8] - Operating cash flow net amount for the reporting period was RMB 15.73 million, a decrease of 54.65% year-on-year, primarily due to increased cash payments for goods[23] - Investment cash flow net amount for the reporting period was RMB -40.63 million, a decrease of 306.28% year-on-year, mainly due to reduced cash inflows from matured financial products[23] - Cash flow from operating activities generated CNY 15,734,624.94, a decrease of 54.7% from CNY 34,692,498.26 in the previous year[60] - Cash flow from investment activities was negative at CNY -40,625,462.77, worsening from CNY -9,999,343.16 year-over-year[61] - Cash flow from financing activities resulted in a net outflow of CNY -14,135,960.23, compared to CNY -39,701,762.81 in the same period last year[61] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,909[12] - The company has a total of CNY 24,765,761.38 in deferred income, which may indicate future revenue recognition opportunities[73] - The company has a total of CNY 3,700,509.99 in contract liabilities, suggesting ongoing commitments to customers[73] Expenses - Sales expenses for the reporting period were RMB 13.22 million, a year-on-year decrease of 48.7%, mainly due to the reclassification of transportation costs into operating costs[22] - Research and development expenses for the quarter were CNY 4,394,579.59, slightly up from CNY 4,242,879.71 year-over-year[42] - The company reported a financial expense of CNY 740,806.07, compared to a financial income of CNY -203,148.48 in the previous period[42] - Sales expenses decreased to CNY 13,218,369.30 from CNY 25,766,229.82, indicating improved cost management[51] Investment Activities - The company reported non-recurring gains and losses totaling CNY 7,192,194.91 for the year-to-date period[10] - The company’s investment income for the quarter was CNY 2,962,723.64, down from CNY 4,034,308.34, suggesting a need for strategic review in investment activities[51]